Paper Details

  1. Home
  2. Paper Details

A comparative study of daily and twice-weekly continuation regimens of tuberculosis chemotherapy, including a comparison of two durations of sanatorium treatment.

Author:

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A study of tuberculosis patients found that three different continuation regimens, administered after an initial 3-month course of standard triple therapy, were all highly effective after 3 years. The regimens included daily PAS plus isoniazid, twice-weekly streptomycin plus isoniazid, and a combination of twice-weekly and once-weekly streptomycin plus isoniazid. While all regimens were equally effective, the intermittent regimens provided better control over treatment.
Paper Details　
Original Abstract of the Article :
Further results are presented of a controlled clinical trial carried out in Czechoslovakia of chemotherapeutic regimens in pulmonary tuberculosis in which, following 3 months of standard triple chemotherapy, 3 continuation regimens allocated at random for up to 18 or 24 months were compared. These w...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0041-3879(76)90016-7

データ提供：米国国立医学図書館（NLM）

Comparing Tuberculosis Chemotherapy Regimens: A Desert of Treatments

Tuberculosis, a persistent infectious disease, is like a desert mirage, often appearing and disappearing but leaving a lasting impact. This study, conducted in Czechoslovakia, aimed to compare the effectiveness of different continuation regimens for tuberculosis chemotherapy. The researchers compared three regimens: PAS plus isoniazid daily, streptomycin plus isoniazid twice a week, and streptomycin plus isoniazid twice a week initially transitioning to once a week. All regimens were administered after an initial 3-month period of standard triple chemotherapy. The results showed that all three regimens were highly effective in controlling tuberculosis, with no significant differences observed after 3 years. The researchers concluded that the intermittent regimens offered the advantage of stricter control over the patient's chemotherapy.

Effective Regimens: Navigating the Desert of Tuberculosis

Imagine these regimens as different paths through the desert of tuberculosis. While all paths led to effective control of the disease, the intermittent regimens offered a more efficient and manageable approach, allowing for better control over the treatment process.

Navigating the Desert of Tuberculosis: Treatment Options and Considerations

This study provides valuable insights into the effectiveness of different tuberculosis chemotherapy regimens. It highlights the importance of individualized treatment strategies, taking into account factors such as patient adherence and the potential benefits of intermittent therapies.

Dr. Camel's Conclusion

This study, like a caravan carefully navigating the desert of tuberculosis treatment, demonstrates the effectiveness of different regimens. By understanding the nuances of each regimen, healthcare professionals can tailor treatment approaches to ensure the best outcomes for patients battling this persistent disease.

Date :
  1. Date Completed 1976-09-25
  2. Date Revised 2019-09-07
Further Info :

Pubmed ID

781965

DOI: Digital Object Identifier

10.1016/0041-3879(76)90016-7

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.